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Background: In boys with suspected partial androgen insensitivity syndrome (PAIS), systematic
evidence that supports the long-term prognostic value of identifying a mutation in the androgen
receptor gene (AR) is lacking.
Objective: To assess the clinical characteristics and long-term outcomes in young men with sus-
pected PAIS in relation to the results of AR analysis.
Methods: Through the International Disorders of Sex Development Registry, clinical information
was gathered on young men suspected of having PAIS (n 52) who presented before the age of
16 years and had genetic analysis of AR.
Results: Themedian ages at presentation and at the time of the study were 1month (range, 1 day to
16years)and22years (range,16to52years), respectively.Of thecohort,29men(56%)had20different
ARmutations reported.At diagnosis, themedianexternalmasculinization scoreswere 7 and6 in cases
with and without AR mutation, respectively (P  .9), and median current external masculinization
scores were 9 and 10, respectively (P  .28). Thirty-five men (67%) required at least one surgical
procedure, and those with amutationweremore likely to requiremultiple surgeries for hypospadias
(P .004). All cases with anARmutation had gynecomastia, compared to 9%of thosewithout anAR
mutation. Of the six men who had a mastectomy, five (83%) had an ARmutation.
Conclusions:Boyswithgenetically confirmedPAIS are likely to have apoorer clinical outcome than
those with XY DSD, with normal T synthesis, and without an identifiable AR mutation. Routine
genetic analysis of AR to confirm PAIS informs long-term prognosis and management. (J Clin
Endocrinol Metab 101: 3959–3967, 2016)
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Androgens play an important role in a wide range ofbiological processes including sexualdifferentiation
(1). Defects in androgen synthesis or action in a 46, XY
infant can give rise to a very variable phenotype, ranging
fromnormal female external genitalia to various grades of
undermasculinization of male genitalia (2). Boys with no
evidence of gonadal dysgenesis and normal androgen syn-
thesis have often been considered to have partial androgen
insensitivity syndrome (PAIS), a condition that usually
arises due to a mutation in the androgen receptor (AR)
gene (AR) (3). Although PAISmay be the commonest phe-
notypic entity that is suspected in 46, XY disorders of sex
development (DSD), 30% of boys may have confirmed
PAIS with a detectable mutation in AR (4). A mutation in
AR may also be found in boys with relatively minimal
signs of undermasculinization (5), and because most of
these infants will have no clear evidence of a disorder of
androgen synthesis or action (6), it is unclear whether all
of these boys merit routine genetic analysis of AR. Al-
though there is some evidence that young men with PAIS
may have a suboptimal medical and surgical outcome (7),
the rarity of this condition has prevented a conclusive
studyon the long-termclinical outcomeofboyspresenting
with thewide range of phenotype that has been previously
reported in boys with a confirmed mutation in AR (3). It
is possible that androgen insensitivity may be due to a
molecular abnormality in a pathway downstream of the
AR (8) or in the noncoding region adjacent to AR (4). A
clear understanding of the long-term phenotype of men
with PAISwill also allow improved diagnostic genetic tar-
geting in those cases that have the PAIS phenotype but no
detectable mutation in AR.
With the advent of the International DSD (I-DSD)Reg-
istry (9), a study of the long-term outcomes of rare con-
ditions such as PAIS in a sufficiently large cohort has now
become feasible. The current study was performed to as-
sess whether the long-term outcome with a particular fo-
cus on genital development and gonadal function in boys
with a genetically confirmed AR mutation was different
from those with a similar phenotype but without an iden-
tifiable AR mutation.
Patients and Methods
All 46, XY male patients registered as having PAIS who were
under the age of 16 years at the time of diagnosis and 16 years
old at the time of data collection were identified in the I-DSD
Registry. The registry is an international database of pseudo-
anonymized information on people with DSD, and the data are
deposited by their clinicians after receiving informed consent
from the patients or their guardians. Details of the development
of the registry and its recent use have been previously reported
(9, 10), and its standard operating protocol is available at
http://www.gla.ac.uk/schools/medicine/research/childhealth/
i-dsdproject/thei-dsdregistry/standardoperatingprotocol/
(accessed March 28, 2016). The registry is approved by the Na-
tional Research Ethics Service in the United Kingdom as a re-
search database of information that is collected as part of routine
clinical care. All I-DSD Registry users who had registered an
eligible case were approached for results of AR gene analysis,
clinical characteristics at first and most recent presentations,
biochemical characteristics, and subsequent management. The
registry also collects information on the extent of certainty of
diagnosis, and this is categorized as “clinical certainty,” “bio-
chemical certainty,” and “genetic certainty.” In this study, all
included cases had normal testes function andT synthesis. How-
ever, cases of suspected PAIS that did not reach genetic certainty
because they did not have a genetic confirmation despite AR
analysiswere not referred to as having PAIS so that they could be
differentiated fromthe cases of PAIS that actually hadamutation
in AR. Details of the information collected are summarized in
Supplemental Table 1. The external masculinization score
(EMS) was calculated as previously described (12). Briefly, the
EMS is a composite score that is based on the site of the urethral
meatus, location of the gonads, the presence of amicropenis, and
the presence of labioscrotal fusion; normal male external geni-
talia as would be expected in a boy would have a score of 12,
whereas normal female external genitalia would have a score of
0. Historical records of serum LH, FSH, and T as measured by
local immunoassays were collected if available. All cases were
studied using full sequencing of the coding regions and intron/
exon boundaries (exons 2–8), with some cases undergoing anal-
ysis of exon 1.
Continuous variables were described as medians and ranges,
and intergroup comparison for these variableswas performedby
Mann-Whitney U tests. A Fisher exact test was performed to
compare proportions in different groups. The level of P  .05
was considered to be statistically significant, and all analyses
were performed using XLStat (Addinsoft).
Results
PAIS and AR mutation status
Among the 1892 records in the I-DSD Registry at the
time of the study, there were 1225 (65%) cases with a 46,
XYkaryotype.Of these46,XYDSDcases, 154 (13%)had
been categorized as PAIS, and 60 of these 154 (39%)were
identified as men over the age of 16 years. Details on AR
mutation testingandclinical informationwereavailable in
52 of the 60 (87%)men. In this latter cohort, 29menwere
identified as having 22 different ARmutations within ex-
ons 2 to 8 (Table 1) and, therefore, had genetically con-
firmed PAIS. Five mutations (D565N, Q825K, L712F,
R855H, andR846H)were observedmore thanonce, all in
related individuals. Despite having the same genetic mu-
tation, the clinical phenotype at initial presentation varied
widely (Table 1). One man who presented at birth with
distal hypospadias had two ARmutations, including one
in exon 2 (L545P) and one in exon 5 (T739C). The re-
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maining 23 caseswhodid not have amutation inARwere,
for the purpose of this study, referred to as XY DSD.
Clinical features at first presentation
Of the 52 men included in this study, the initial pre-
sentation was reported as hypospadias in 28 (54%), am-
biguous genitalia in 11 (39%), and a positive family his-
tory in two (7%). Inolderboys, gynecomastiawasanother
clinical presentation, but this was only encountered as a
reason for presentation in thosewith anARmutation (Fig-
ure 1); none of theXYDSDcaseswithout anARmutation
presented in adolescence, and because of this skew, the
median age at presentation tended to be higher in the
group with an AR mutation (Table 2). There was no sig-
nificant difference in the number of cases with or without
an AR mutation who presented with hypospadias, unde-
scended testes, ormicropenis, and themedian EMS at first
presentation in the two groupswas similar at 7 (2, 12) and
6 (2, 12), respectively. On excluding the cases who had
presented with a positive family history or gynecomastia,
the median EMS in the group with an AR mutation and
those without was similar at 5 (2, 10) and 6 (2, 12),
respectively.
Clinical biochemistry at first presentation
SerumT tended to be higher in subjects that had anAR
mutation, but the difference was not statistically signifi-
cant (Table 3). Of 29 cases with an AR mutation, serum
LH and FSH were available in 23 and 22 cases, respec-
tively, and there were also no significant differences be-
tween the cases with and without an AR mutation. Al-
though the median LH:FSH ratio in those with and
without anARmutationwas similar at 1.1 (0.01, 102) and
1.3 (0.3, 6.7), respectively, the T:LH was significantly
higher at 1.9 (0.1, 13.3) compared to0.9 (0.1, 1.7) in those
with a mutation (P  .02) (Table 3). In a separate com-
parison of the 15 infants who presented before the age of
6months andwho had anARmutation and the 16 infants
without an AR mutation, none of the biochemical values
above showed any statistical difference.
Current clinical status
Irrespective of ARmutation status, undermasculiniza-
tion was frequently observed at the most recent clinical
presentation (Table 2). On excluding the men who had
presented because of a positive family history or gyneco-
mastia, themedian EMS values in the caseswith andwith-
Table 1. Mutations and Clinical Features of All Genetically Confirmed Cases of PAIS With a Mutation in AR
Age at First
Presentation
EMS At First
Presentation
Clinical
Features
Family
History
EMS at Last
Assessment
Testos
Treatment
AR
Mutation
1 d 2 H, M, B Y 9 N R855H
1 d 4 H, M, B N 4 N R855H
1 mo 2 H, M, B N 5 Y D565N
1 mo 3 H, M, B Y 6 Y S598A
1 mo 4 H, M, B N 6 Y L839P
1 mo 4 H, M, B Y 9 N R855H
1 mo 6 H, B N 9 Y G868L*
1 mo 6 H, B Y 8 Y L712F
1 mo 6 H, M, U N 9 Y L839I*
1 mo 8 H, M, U N 10 Y A840C
1 mo 8 M, U Y 9 Y L712F
1 mo 10 H N 12 N R846H
3 mo 6 H N 12 N S597R
3 mo 7 H, M N 10 Y L545P*, T739C*
3 mo 8 M, U Y 9 Y L712F
1 y 10 H N 12 Y A608G
2 y 2 H, M, U Y 5 Y D565N
5 y 9 M Y 12 N Q825K
6 y 12 None Y 12 Y Q825K
11 y 4 H, M, B N 6 N F754L
11 y 5 H, G N 8 Y Q799E
11 y 12 G N 12 N P695S*
12 y 7 H, B N 9 N G789A*
12 y 9 G Y 10 Y Q825K
12 y 12 G Y 12 N R846H
13 y 6 H, M N 9 N A596T
13 y 9 M, G N 12 N N757S
16 y 9 M, G N 12 N Q825K
16 y 12 G N 12 Y Q825K
Abbreviations: H, hypospadias; M, micropenis; G, gynecomastia; U, unilateral undescended testis; B, bilateral undescended testes; Testos,
testosterone; Y, yes; N, no. All variants are reported in the Androgen Receptor Genes Mutation Database (11) except those marked with asterisks.
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out an AR mutation were 6 (3, 12) and 9 (2, 12), respec-
tively. In the whole cohort of 52 cases, 25 (42%) had
required T therapy at puberty, and the regimen that was
used was very variable (Figure 2). Testosterone adminis-
tration was more common in the men with an AR muta-
tion (Figure 2). Of the 16 men with an AR mutation and
six without an ARmutation who had T therapy, a micro-
penis in adulthood was reported in two (13%) and zero
(0%) cases, respectively. Of the 29 cases who had an AR
mutation, 20 had hypospadias at initial presentation and
six (33%) continued to have a hypospadias despite surgi-
cal repair, whereas only one of the 20 with hypospadias
and no AR mutation continued to have a hypospadias
(Table 2). In addition, those with an AR mutation were
more likely to have a greater number of surgical proce-
dures for their hypospadias repair (Figure 2), ranging up
to 10 in one man. All men with an AR mutation had gy-
necomastia, compared to only 10%ofmenwithout amu-
tation (Table 2). Six men had gynecomastia that was se-
vere enough to require mastectomy (Figure 2); five (83%)
of these six men had an AR mutation. Among the cases
without a mutation, there was one person who had mi-
Figure 1. Consort diagram with brief description of main reason for presentation in the genetically confirmed cases of PAIS with a mutation in AR
(AR Mutation) and those cases that were XY DSD with normal androgen synthesis but had no mutation in AR (No AR Mutation). FH, family history.
Table 2. Comparison of Clinical Characteristics of Genetically Confirmed Cases of PAIS With a Mutation in AR and
Cases That Were XY DSD With Normal Androgen Synthesis But Had No Mutation in AR at First Presentation and Last
Assessment
AR
Mutation
No AR
Mutation P
n 29 23
Age at first presentation, ya 0.3 (0, 16.4) 0.1 (0, 10.0) .05
Age at last assessment, ya 21 (16, 52) 24 (18, 30) .64
EMS at first presentationa 7 (2, 12) 6 (2, 12) .9
EMS at last assessmenta 9 (3, 12) 10 (7, 12) .28
Hypospadias at first presentation (Prox, Mid, Dis, NK) 20 (69) (15, 2, 1, 2) 20 (87) (13, 0, 6, 1) .19
Hypospadias at last assessment 7 (24) 3 (13) .12
Undescended testis at first presentation 2 (7) 0 (0) .49
Undescended testis at last assessment 2 (7) 0 (0) .49
Bilat undescended testes at first presentation 7 (24) 11 (48) .09
Bilat undescended testes at last assessment 0 (0) 0 (0) 1
Micropenis at first presentation 13 (45) 6 (26) .25
Micropenis at last assessment 5 (17) 1 (4) .21
Gynecomastia at first presentation 7 (24) 0 (0) .01
Gynecomastia at last assessment 29 (100) 2 (9) .001
Abbreviations: Bilat, bilateral; Prox, proximal; Mid, midshaft; Dis, distal; NK, not known. Data are expressed as number (percentage) unless
specified otherwise.
a Continuous variables expressed as median (range).
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cropenis, one who had persistent hypospadias, and two
with gynecomastia (Table 2).
Clinical biochemistry at last assessment
In those with an AR mutation, serum LH and T were
significantly higher than in thosewithout anARmutation
(Table 3). Both LH:FSH and T:LH ratios tended to be
higher in menwith amutation, and the difference reached
statistical significance for the latter (Table 3). Using LH
and FSH values of 12 IU/L as a reference for 2 SD above
the mean for healthy men (13), it was apparent that in
those with an AR mutation, serum LH and FSH were
higher than this cutoff in 10 of 24 (42%) and seven of 22
(32%) cases, respectively. Only one of these 18 men had
a history of bilateral undescended testes. Of the men with
no AR mutation, none of nine had a serum LH above 12
IU/L, and two of seven (29%) had a raised FSH. Both
LH:FSH and T:LH ratios tended to be higher in men with
a mutation, but the difference was not significantly dif-
ferent (Table 3).
Other outcomes
The provision of psychological input was reported in
11of52 (21%)cases, and sevenof these11menhadanAR
mutation. Of these 11 men, one (9%) had declined a psy-
chological referral, eight (73%)were receiving psycholog-
ical support at the last assessment, and two (18%) had
previously received input but were no longer actively in-
volved with this. Fertility data were available for 14 men
with an AR mutation and four without a mutation who
werebetween18and34years of age at the timeof themost
recent presentation. Among this cohort, two with an AR
mutation had undergone sperm analysis that had demon-
strated azoospermia (FSH, 89 and 86 IU/L at last presen-
tation). One of these men had one undescended testis re-
quiring orchiopexy, and the other
man had undergone bilateral or-
chiopexy. Only two men had off-
spring; one of thesemen did not have
anARmutationandhad required as-
sisted conception after sperm analy-
sis demonstrated oligospermia, and
the other, who had anARmutation,
had conceived naturally.Noneof the
men in this study had any record of
tumor-related events. Two of the 29
menwith anARmutation (7%)were
noted to have obesity with body
mass indices of 28 and 30 kg/m2; one
had undergone assessment for possi-
ble bariatric surgery, and the other
had refused any dietetic advice.
None of the men had any recorded
Figure 2. Testosterone therapy (left) and surgical encounters (right) in genetically confirmed
cases of PAIS with a mutation in AR (AR mutation) and those cases that were XY DSD with
normal androgen synthesis but had no mutation in AR (No AR mutation). *, P  .05.
Table 3. Comparison of Biochemical Characteristics of Genetically Confirmed Cases of PAIS With a Mutation in AR
and Cases That Were XYD DSD with Normal Androgen Synthesis But Had No Mutation in AR at First Presentation
and Last Assessment
AR
Mutation
No AR
Mutation P
Age at first presentation, y 0.3 (0, 16.4) 0.1 (0, 10.0) .05
Age at last assessment, y 21 (16, 52) 24 (18, 30) .64
Serum LH at first presentation, IU/L 4.5 (0.04, 21.1) (23) 3.3 (0.1, 6.7) (9) .32
Serum LH at last assessment, IU/L 11.2 (1.8, 57) (24) 4.3 (0.1, 7.7) (9) .002
Serum FSH at first presentation, IU/L 1.9 (0.1, 39.8) (22) 1.7 (0.2, 5.5) (11) .5
Serum FSH at last assessment, IU/L 4.7 (1.2, 89.0) (22) 5.6 (0.3, 12.8) (7) .56
Serum LH:FSH at first presentation 1.1 (0.01, 102) (16) 1.3 (0.3, 6.7) (5) .77
Serum LH:FSH at last assessment 1.7 (0.2, 13.5) (18) 0.7 (0.1, 2.3) (7) .22
Serum T at first presentation, nmol/L 8.6 (0.01, 60.8) (23) 2.8 (0.1, 21.5) (15) .09
Serum T at last assessment, nmol/L 18.7 (4.8, 68.3) (24) 10.2 (3.6, 23.4) (8) .03
Serum T:LH at first presentation 1.9 (0.1,13.3) (21) 0.9 (0.1, 1.7) (7) .02
Serum T:LH at last assessment 2.3 (0.2, 12.7) (24) 1.8 (0.8, 3.2) (4) .57
Results of these parameters were available in a variable number of cases and are expressed as median (range) (number).
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investigations for concerns regarding bone mineral den-
sity or cardiometabolic health.
Discussion
The current report represents the largest study on clinical
outcomes in young men with XY DSD and normal T syn-
thesis and who were previously suspected of having PAIS
in childhood and adolescence. The study not only raises
concerns about the long-term outcome in those men with
PAIS but also strengthens the clinical rationale for the
routine genetic analysis of AR in boys where there is a
clinical suspicion of PAIS.
Access to the I-DSDRegistry allowed the identification
of a sufficiently large group of male cases of 46, XY DSD
with a variable extent of undermasculinization at initial
presentation and who had a clinical phenotype consistent
with PAIS. The difficulty in diagnosis was illustrated by
the fact that there was no clear difference in the physical
and biochemical features that were assessed at presenta-
tion in those cases with an identifiable mutation in AR
compared to the ones without a mutation. Although
higher T concentrations and T:LH ratios were encoun-
tered in the cases with an ARmutation, there was a large
overlap between the two groups and as observed previ-
ously (13, 14).
As young men, those with an AR mutation tended to
have a worse prognosis for virilization as reflected by the
gynecomastia. These men were also more likely to have
hypospadias and micropenis, but this difference did not
reach statistical significance. In addition, these men with
an AR mutation were more likely to have had T therapy.
A variable level of virilization after androgen therapy has
been reported in PAIS (8) and may reflect the lack of stan-
dardization of therapy,with reports often limited to single
case reports (16). This variability in virilization in PAIS
and the wide range of androgen regimens that are used
were clearly evident in the current study. The gynecomas-
tia, which was universally encountered in all the young
men with an AR mutation, confirms previous reports (8,
17). Given that these men have severe and persistent gy-
necomastia that ismore likely to lead tomastectomy, early
knowledge ofAR genetic statuswould allow the provision
of informed guidance to the adolescent.
The current report has identified a clear association
between AR status and the outcome of hypospadias sur-
gery. Most cases of hypospadias require one or two sur-
gical procedures (18); however, the current study clearly
shows that theyoungmenwithanARmutationweremore
likely to have multiple procedures. Given that the relative
proportions of the type of hypospadias was similar in the
two study groups and that the cases were spread over all
the centers, the different outcome cannot be due to case or
operator bias. Thus, the poor results are more likely to be
related to defective androgen signaling and its links to
tissue healing (19). Large-scale studies of hypospadias
outcome regularly report a measurable incidence of failed
repair (18, 20), but the genetic status of these cases has not
been reported anddeserves further study. It is possible that
the knowledge of the status ofARmay guide the clinician
toward a different approach to surgical management and
may also allow improved preparation and counseling of
the patient. One-fifth of the studied cohort was reported
to have been offered clinical psychology input and, given
the concerns raised previously about psychosexual out-
come (21) and gender dysphoria (22) in adults with PAIS,
wewould recommend that clinical psychology assessment
and input should be routinely offered, especially in those
cases that have a mutation in AR.
Previous cross-sectional studies of the hypothalamic-
pituitary-gonadal axis in genetically confirmed cases of
PAIS, performed at a range of ages in childhood and ad-
olescence, have reported concerns about testicular func-
tion, as reflected by a bluntedT rise after human chorionic
gonadotropin stimulation as well as raised gonadotropins
(5, 7). The description of raised gonadotropins has pri-
marily been highlighted for LH and was attributed to a
lack of androgen feedback on LH secretion (15, 23, 24). A
raised LH and T level may be a clue to the diagnosis of
androgen insensitivity syndrome, and although the abso-
lute values of these markers were not remarkable in the
current study, the T:LH ratio was higher at first presen-
tation in the cases with an AR mutation. It is likely that
suppressionofLHsecretion is partially dependent onboth
T and estradiol (25), and the raised T:LH ratio may be a
reflection of androgen insensitivity in a situation where T
can still be aromatized to estradiol. Although the current
study shows that LH is more likely to be raised at last
presentation, in a substantial subset of cases, FSHwas also
raised, highlighting the possibility of progressive primary
gonadal failure in boyswith PAIS. Although in some cases
the testicular failure may have been related to maldescent
of the testis or the subsequent orchiopexy, most of the
cases with high gonadotropins did not have undescended
testes, and it is possible that this biochemical picture may
reflect the role of androgens in testes development and
maintenance (26, 27). This is in line with the histological
observation that testes in men with PAIS are prone to fi-
brosis and loss of testicular architecture (our unpublished
observation).
Although over 400 AR mutations have now been de-
scribed in androgen insensitivity syndrome (11), the cor-
relation between phenotype and genotype has remained
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very poor, with even wide phenotypic variability between
individuals with the same mutation and within the same
family (28); this variability was also observed in the cur-
rent cohort. It is still possible that knowledge of a specific
AR mutation as well as the function of the defective AR
protein may assist management (29). However, the cur-
rent data suggest that the identification of anARmutation
in cases of XYDSDmay itself be sufficient to predict poor
prognosis and personalize long-term management. A re-
cent surveyofpediatric endocrine centershas revealed that
43% would routinely consider AR analysis in 46, XY in-
fants with genital ambiguity (30). Given that the cases in
the current study had a variable level of undermasculin-
ization, our experience would suggest that the threshold
for considering genetic analysis forAR should be lowered
in all cases of hypospadias that are proximal or associated
with micropenis or undescended testes, especially when
there are no associated concerns about T synthesis. In
terms of EMS, this would be equivalent to a score of 11 or
below and consistent with other recommendations (31).
Other features, such as a positive family history or the
presence of gynecomastia in an adolescent, would also
lower the threshold.
Knowledge of the biology and genetics of sex develop-
ment as well as the technology employed for diagnostic
genetics has progressed considerably since the period
when the cases in this cohort were analyzed (32). Almost
all of the cases in the current cohort would have been
analyzed in research laboratories with different protocols
and different levels of success at sequencing the first exon
of AR and with variable depth of coverage of the intronic
region. The current study emphasizes the need for revis-
iting the genetic analysis of AR in those adolescents and
young men who did not have a mutation identified before
but who may have features such as gynecomastia, persis-
tent hypogonadism, and poor outcome after hypospadias
repair. With the availability of quality accredited labora-
tories offering analysis of a wide panel of genes associated
with sex development as well as increased reliance on
whole-genome sequencing (33), it is quite likely that fur-
ther defects in AR or mutations in other genes associated
with DSDmay be revealed. By targeting analysis in young
men with a clearer phenotype of androgen insensitivity, it
is also possible that future research can bemore effectively
directed at understanding the wider clinical relevance of the
androgen-signaling pathway downstream of AR as well as
the noncanonical pathways of androgen signaling (34).
In older men with hypogonadism, cardiovascular mor-
bidity, impaired glucose tolerance, and osteoporosis pose
the greatest health and economic burden (35), and there is
sufficient evidence that young men with primary hypogo-
nadism may also suffer from these effects (36–39). Even
mildly impaired Leydig cell function in otherwise healthy
subjects with low-normal T and elevated LH levels is as-
sociated with increased mortality and morbidity (39).
Given that the men with confirmed PAIS with a defect in
ARmay be severely hypogonadal, as suggested by the cur-
rent findings, the need for careful monitoring of the wider
cardiometabolic consequences of hypogonadism requires
strong consideration. Successful fertilityhasbeen reported
in men with PAIS using assisted conception techniques
(17, 40). In the current study, one of the young men with
an AR mutation was reported to have an offspring natu-
rally, indicating that spontaneous fertility is possible in
young men with confirmed PAIS.
Although there are inherent weaknesses in performing
a retrospective study that relies on data collected from
multiple centers, the power of the study rests in the size of
the cohort and the small number of clear and measurable
outcomes that were collected. Although it is reassuring
that all the participating centers routinely collected the
information that was sought, the current study highlights
the need for a standardized assessment of all boys who are
suspected of having long-term hypogonadism, especially
as they approach the age of puberty. It is possible that the
cases entered into the registry suffered from selection bias
and inclusion of the cases that were older at presentation
also introduced further bias. However, this risk was mit-
igated by the discrete comparison of the group of children
who presented at an early age. Increasingly, the diagnosis
of PAIS is only reserved for those cases that have a con-
firmedmutation inAR, and it is possible that a number of
cases with no AR mutation have not been entered in the
I-DSD Registry because PAIS and differences in the use of
the registrymay have introduced further bias.However, it
is likely that this change indiagnostic practicewouldapply
to younger cases than those reported here. Finally, a gen-
otype-phenotype correlation was not explored in this
study, but this will becomemore feasible as the number of
cases with genetically confirmed PAIS that reach adult-
hood increases over the next decade.
In conclusion, this study represents the largest cohort to
date of young men who presented in childhood with clin-
ical features suggestive of PAIS. There is clear evidence
that genetically confirmed cases of PAIS with a mutation
inAR aremore likely to have aworsemedical and surgical
outcome as young men. Thus, routine genetic analysis of
AR in boys suspected of PAIS is recommended to guide
long-term prognosis and tailor management.
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